Lv0
0 积分 2024-11-03 加入
Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial
21小时前
已完结
Lisocabtagene maraleucel in patients with relapsed or refractory marginal zone lymphoma (TRANSCEND FL): primary analysis results from the global, multicohort, single-arm, phase 2 study
21小时前
已完结
Chronic lymphocytic leukaemia
22小时前
已完结
Phase 2 trial of rituximab with either pentostatin or bendamustine for multiply relapsed or refractory hairy cell leukemia
1天前
求助中
Phase 2 trial of rituximab with either pentostatin or bendamustine for multiply relapsed or refractory hairy cell leukemia
1天前
已关闭
How I treat refractory/relapsed hairy cell leukemia with BRAF inhibitors
1天前
已关闭
Hairy cell leukemia 2024: Update on diagnosis, risk‐stratification, and treatment—Annual updates in hematological malignancies
1天前
已完结
Analysis of factors associated with patients’ global impression of change scores in inpatients with peripheral facial palsy: A retrospective study at a Korean Medicine Hospital
21天前
已关闭
Patient global impression of change in pediatric chronic pain clinical trials: A review and secondary analysis of randomized controlled trial data
21天前
已关闭
Advances in the discovery of selective NaV1.8 inhibitors for pain management
22天前
已完结
皖公网安备34019202002308
